These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 19793706)

  • 1. Cutaneous eruption related to human epidermal growth factor receptor inhibitors in stage IV colon cancer.
    Guzman L; Kozloff M; Wallace J; Starr A
    Clin J Oncol Nurs; 2009 Oct; 13(5):491-3. PubMed ID: 19793706
    [No Abstract]   [Full Text] [Related]  

  • 2. Nail toxicity associated with epidermal growth factor receptor inhibitor therapy.
    Fox LP
    J Am Acad Dermatol; 2007 Mar; 56(3):460-5. PubMed ID: 17147969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psychosocial impact of cutaneous toxicities associated with epidermal growth factor receptor-inhibitor treatment.
    White KJ; Roydhouse JK; Scott K
    Clin J Oncol Nurs; 2011 Feb; 15(1):88-96. PubMed ID: 21278044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cutaneous reactions related to systemic immunomodulators and targeted therapeutics.
    Hammond-Thelin LA
    Dermatol Clin; 2008 Jan; 26(1):121-59, ix. PubMed ID: 18023775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors.
    Balagula Y; Garbe C; Myskowski PL; Hauschild A; Rapoport BL; Boers-Doets CB; Lacouture ME
    Int J Dermatol; 2011 Feb; 50(2):129-46. PubMed ID: 21244375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence-based treatment options for the management of skin toxicities associated with epidermal growth factor receptor inhibitors.
    Tan EH; Chan A
    Ann Pharmacother; 2009 Oct; 43(10):1658-66. PubMed ID: 19755624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidermal growth factor receptor as a target in cancer therapy.
    Kim ES
    J Natl Compr Canc Netw; 2003 Jan; 1 Suppl 1():S87-95. PubMed ID: 19795581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The changing paradigm of colorectal cancer therapy: the impact of vascular endothelial growth factor and epidermal growth factor and epidermal growth factor receptor inhibition. Introduction.
    Chase JL
    Pharmacotherapy; 2008 Nov; 28(11 Pt 2):17S. PubMed ID: 18980547
    [No Abstract]   [Full Text] [Related]  

  • 9. The PRIDE (Papulopustules and/or paronychia, Regulatory abnormalities of hair growth, Itching, and Dryness due to Epidermal growth factor receptor inhibitors) syndrome.
    Lacouture ME; Lai SE
    Br J Dermatol; 2006 Oct; 155(4):852-4. PubMed ID: 16965448
    [No Abstract]   [Full Text] [Related]  

  • 10. Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities.
    Modjtahedi H; Essapen S
    Anticancer Drugs; 2009 Nov; 20(10):851-5. PubMed ID: 19826350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of hypomagnesemia in cancer patients receiving chemotherapy.
    Saif MW
    J Support Oncol; 2008; 6(5):243-8. PubMed ID: 18551863
    [No Abstract]   [Full Text] [Related]  

  • 12. New targeted therapies for non-small-cell lung cancer: a focus on the epidermal growth factor receptor.
    Crawford J
    J Natl Compr Canc Netw; 2003 Jan; 1 Suppl 1():S78-86. PubMed ID: 19795580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does cetuximab cause small bowel perforation?
    Ozturk MA; Eren OO; Oyan B
    J BUON; 2014; 19(3):865. PubMed ID: 25261682
    [No Abstract]   [Full Text] [Related]  

  • 14. [Skin disorders].
    Uhara H
    Nihon Rinsho; 2015 Feb; 73 Suppl 2():450-3. PubMed ID: 25831801
    [No Abstract]   [Full Text] [Related]  

  • 15. Unique presentations of epidermal growth factor receptor inhibitor-induced papulopustular eruption related to bacterial superinfection.
    Wiznia LE; Choi JN
    Dermatol Online J; 2013 Mar; 19(3):8. PubMed ID: 23552005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Geographic distribution of lapatinib-induced skin rash: sparing of abdominal skin persists in the transverse rectus abdominis myocutaneous flap.
    Lin NU; Kasparian E; Morganstern DE; Beard C
    J Clin Oncol; 2009 Dec; 27(34):e218-9. PubMed ID: 19786662
    [No Abstract]   [Full Text] [Related]  

  • 17. New drug therapies and their effect on the skin.
    Treudler R
    J Dtsch Dermatol Ges; 2009 Jul; 7(7):623-37. PubMed ID: 19614812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive biomarkers in the development of oncology drugs: a therapeutic industry perspective.
    Fine BM; Amler L
    Clin Pharmacol Ther; 2009 May; 85(5):535-8. PubMed ID: 19295504
    [No Abstract]   [Full Text] [Related]  

  • 19. Is there any alternative to conventional anticancer treatment? Comments to: Trustworthy alteration and improvement in adjuvant treatment of colon cancer. Ali Harlak, Atilla Soran Med Sci Monit, 2006; 12(3): RA46-52.
    Malkov SV; Markelov VV; Barabanschikov BI; Polozov GY; Trushin MV
    Med Sci Monit; 2006 Aug; 12(8):LE16. PubMed ID: 16865073
    [No Abstract]   [Full Text] [Related]  

  • 20. Epidermal pseudocarcinomatous hyperplasia with underlying epidermal growth factor-producing cutaneous CD30-positive lymphoproliferative disorder.
    Kawachi Y; Taguchi S; Fujisawa Y; Furuta J; Nakamura Y; Ishii Y; Takahashi T; Otsuka F
    J Eur Acad Dermatol Venereol; 2009 Feb; 23(2):181-3. PubMed ID: 18429982
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.